Palisade Bio, Inc. (PALI) — 10-Q Filings

10-Q Filings (6)

• Palisade Bio Narrows Losses, Secures $138M Equity Infusion — Nov 10, 2025 Risk: medium
  PALISADE BIO, INC. (PALI) reported a net loss of $2.868 million for the three months ended September 30, 2025, an improvement from a $3.487 million net loss in
• Palisade Bio Narrows Q2 Loss Amid R&D, G&A Cuts — Aug 11, 2025 Risk: high
  PALISADE BIO, INC. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company's net loss for th
• Palisade Bio Files Q1 2025 10-Q — May 12, 2025 Risk: medium
  Palisade Bio, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition and business operations, including detai
• Palisade Bio Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
  Palisade Bio, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial condition and business operations, including d
• Palisade Bio Files Q2 2024 10-Q, Details Stock Activity — Aug 12, 2024 Risk: medium
  Palisade Bio, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial condition and results of operations, including deta
• Palisade Bio, Inc. Files 10-Q for Period Ending March 31, 2024 — May 13, 2024 Risk:
  PALISADE BIO, INC. (PALI) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Palisade Bio, Inc. filed a 10-Q for the period ending March 31, 2024. Th

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX